TY - JOUR
T1 - Real-world treatment patterns and outcomes in Japanese patients with cervical esophageal cancer
AU - Ohno, Kazuchika
AU - Nasu, Motomi
AU - Matsui, Hidetoshi
AU - Baba, Yoshifumi
AU - Yasuda, Takushi
AU - Sakuma, Jun
AU - Ikeda, Kenichiro
AU - Maruo, Takashi
AU - Okuda, Takumi
AU - Narita, Norihiko
AU - Kato, Hisayuki
AU - Kawasaki, Taiji
AU - Sato, Hiroshi
AU - Tokashiki, Kunihiko
AU - Akisada, Naoki
AU - Ishinaga, Hajime
AU - Akashi, Ken
AU - Okami, Kenji
AU - Murayama, Kosuke
AU - Yamamoto, Soichiro
AU - Kumakura, Yuji
AU - Kawada, Kenro
AU - Shiotani, Akihiro
AU - Asakage, Takahiro
N1 - Publisher Copyright:
© 2022, The Author(s) under exclusive licence to The Japan Esophageal Society.
PY - 2022/10
Y1 - 2022/10
N2 - Background: Cervical esophageal cancer (CEC) carries a poor prognosis; however, due to its low incidence, optimal treatment for CEC remains to be established. The purpose of this study was to clarify the current status of treatment of CEC in Japan and obtain evidence for establishing the appropriate treatment method. Patients and methods: We asked specialist training facilities accredited by the Japanese Broncho-Esophageal Society to register data on CEC cases that received curative treatment from January 2009 to December 2014, and conducted a retrospective review of the clinical data of 302 cases registered from 27 facilities. Results: In regard to the initial therapy, of the 302 patients, 33 had undergone endoscopic resection, 41 had undergone surgery, 67 had received induction chemotherapy (IC), and 143 had received chemoradiotherapy (CRT). There were no significant differences in the 5-year overall survival rates among the patient groups that had received surgery, IC or CRT as the initial treatment; advanced stage and recurrent nerve invasion were identified as independent poor prognostic factors. Among the patients who had received IC or CRT as laryngeal-preserving surgery was not indicated at the time of the initial diagnosis, the functional laryngeal preservation rate at the end of the observation period was 34.8%. Conclusion: Even in patients with advanced CEC, there is the possibility of preserving the larynx by adopting IC or CRT. However, if the laryngeal function cannot be preserved, there is a risk of complications from aspiration pneumonia, so that the choice of treatment should be made carefully.
AB - Background: Cervical esophageal cancer (CEC) carries a poor prognosis; however, due to its low incidence, optimal treatment for CEC remains to be established. The purpose of this study was to clarify the current status of treatment of CEC in Japan and obtain evidence for establishing the appropriate treatment method. Patients and methods: We asked specialist training facilities accredited by the Japanese Broncho-Esophageal Society to register data on CEC cases that received curative treatment from January 2009 to December 2014, and conducted a retrospective review of the clinical data of 302 cases registered from 27 facilities. Results: In regard to the initial therapy, of the 302 patients, 33 had undergone endoscopic resection, 41 had undergone surgery, 67 had received induction chemotherapy (IC), and 143 had received chemoradiotherapy (CRT). There were no significant differences in the 5-year overall survival rates among the patient groups that had received surgery, IC or CRT as the initial treatment; advanced stage and recurrent nerve invasion were identified as independent poor prognostic factors. Among the patients who had received IC or CRT as laryngeal-preserving surgery was not indicated at the time of the initial diagnosis, the functional laryngeal preservation rate at the end of the observation period was 34.8%. Conclusion: Even in patients with advanced CEC, there is the possibility of preserving the larynx by adopting IC or CRT. However, if the laryngeal function cannot be preserved, there is a risk of complications from aspiration pneumonia, so that the choice of treatment should be made carefully.
UR - http://www.scopus.com/inward/record.url?scp=85129484602&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129484602&partnerID=8YFLogxK
U2 - 10.1007/s10388-022-00921-w
DO - 10.1007/s10388-022-00921-w
M3 - Article
C2 - 35525856
AN - SCOPUS:85129484602
SN - 1612-9059
VL - 19
SP - 576
EP - 585
JO - Esophagus
JF - Esophagus
IS - 4
ER -